Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.

Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium.

Workshop on Alcohol Use and Health Disparities 2002: a call to arms.

Topology of factor VIII bound to phosphatidylserine-containing model membranes.

Chronic opioid antagonist treatment selectively regulates trafficking and signaling proteins in mouse spinal cord.

Use of 2-aminopurine fluorescence to examine conformational changes during nucleotide incorporation by DNA polymerase I (Klenow fragment).

Colo-colic intussusception due to intestinal lipomatosis.

Chronic opioid antagonist treatment dose-dependently regulates mu-opioid receptors and trafficking proteins in vivo.

Role of iron in alcoholic liver disease: introduction and summary of the symposium.

Role of S-adenosyl-L-methionine in the treatment of alcoholic liver disease: introduction and summary of the symposium.

Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium.

Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30.

Can alcohol promote aromatization of androgens to estrogens? A review.

Differential incision of bulky carcinogen-DNA adducts by the UvrABC nuclease: comparison of incision rates and the interactions of Uvr subunits with lesions of different structures.

Mutagenicity of nitroaromatic compounds.